# “The injection gives freedom” - An exploration of long-acting injectable HIV treatment acceptance among patients seeking care in two Nairobi tertiary hospitals

**Short Title: Acceptability of long-acting injectable ART**

**Nyukuri Duncan Wekesa[1,2¶*], Abongo Melanie[1&], Anastacia Mbithi[2&], Christine Kundu[1&], Mutai Kenneth[1&], Reena Shah[2¶]**

1. Department of Medicine, Kenyatta National Hospital, Nairobi, Kenya
2. Department of Medicine, Aga Khan University Hospital, Nairobi, Kenya

* Corresponding author dnyukuri@gmail.com

¶These authors contributed equally to this work.

&These authors also contributed equally to this work.

**Keywords:** Long-acting injectable antiretroviral therapy (LAI-ART), Acceptability, People Living with HIV (PLHIV), Kenya

# Abstract

**Background**

Long-acting injectable antiretroviral therapy offers an alternative to daily oral HIV treatment, potentially improving adherence and reducing stigma. While its adoption has been successful in some settings, little is known about its acceptability among people living with HIV in Kenya. This study evaluates the acceptability, barriers, and facilitators of long-acting injectable antiretroviral therapy among people living with HIV in Nairobi, Kenya.

**Methods**

We conducted a mixed-methods study involving 356 people living with HIV receiving care at Kenyatta National Hospital and Aga Khan University Hospital. Quantitative data were collected through structured surveys, while qualitative insights were obtained from three focus group discussions. Descriptive and inferential statistical analyses were performed on survey data, and thematic analysis was applied to focus group discussions transcripts.

**Results**

Overall, 72.2% of participants expressed willingness to switch to long-acting injectable antiretroviral therapy Interest in long-acting injectable antiretroviral therapy was significantly associated with prior knowledge (93.9% vs 80.2%, $p < 0.001$) and more likely among women ((93.5% vs. 83.9%, $p = 0.009$). Key facilitators included the opportunity to stop taking daily pills (71.3%), improved adherence (50.3%) and reduced daily focus on HIV (44.7%). The most frequently cited barriers were fear of side effects (69.7%), needle phobia (32.3%), and distrust in new treatments (20.2%). focus group discussions revealed interest about long-acting injectable antiretroviral therapy's potential to reduce stigma and improve adherence, but also concerns about side effects, access, and the need for robust support systems.

**Conclusion**

People living with HIV in the participating hospitals in Nairobi showed strong interest in long-acting injectable antiretroviral therapy, driven by its potential to improve adherence and reduce stigma. However, concerns about side effects, injections, and access must be addressed. Targeted education, provider training, and healthcare support are crucial for successful implementation.

# Introduction

The HIV epidemic in Sub-Saharan Africa (SSA) remains one of the most significant public health challenges globally. According to the World Health Organization (WHO), SSA accounts for two-thirds of the 40 million people living with HIV (PLHIV) worldwide as of 2023 (1). Kenya mirrors this crisis, with an estimated 1.4 million individuals living with HIV and a prevalence of 3.2% among adults aged 15–49(2). Despite substantial progress in HIV prevention and treatment, persistent gaps remain in achieving universal access to care and ensuring optimal treatment adherence. This emphasizes the urgency of exploring innovative strategies to address the region's unique challenges.

Antiretroviral therapy (ART) has been transformative in controlling the HIV epidemic, with advancements from complex, multi-pill regimens to user-friendly single-pill formulations. However, maintaining consistent adherence to daily oral ART remains a challenge for many PLHIV due to factors such as stigma, pill fatigue, and forgetfulness. Long-acting injectable antiretroviral therapy (LAI-ART) represents a paradigm shift in HIV treatment, offering the potential to overcome these barriers. Administered every two months, LAI-ART offers a discreet and potentially stigma-reducing alternative to daily oral medication. Cabotegravir and Rilpivirine, the first FDA-approved LAI-ART combination(3), have been successfully implemented in numerous countries and demonstrated high efficacy, safety, and tolerability in clinical trials (4,5). Despite its promise, real-world implementation presents significant challenges, including concerns about side effects, needle phobia, healthcare provider capacity, and access to healthcare infrastructure capable of supporting this regimen (6–8).

The existing literature provides important insights into the barriers and facilitators of LAI-ART uptake. For instance, Mantsios et al. (2021) highlighted barriers at multiple levels, including patient adherence to frequent injection appointments, clinic workflow adjustments,

and systemic challenges such as cost and regulatory hurdles(6). Patient perspectives on LAI-ART further reveal diverse experiences and preferences. In a Seattle-based study, concerns about the efficacy, side effects, and injection-related discomfort were prominent, particularly among long-term ART users(7). Patients were hesitant to switch to LAI-ART unless it was as effective as their current regimen. Conversely, studies among HIV-positive sex workers in the Dominican Republic and Tanzania showed broad acceptance of LAI-ART as an alternative to daily oral ART (8). These participants valued the reduced stigma, enhanced privacy, and freedom from the daily pill burden, demonstrating that acceptability can vary significantly across contexts and populations.

In Kenya, research conducted in 2018 explored the acceptability of LAI-ART among adults and youth living with HIV, revealing enthusiasm for the reduced stigma and convenience associated with bi-monthly injections(9). However, the study's limited geographic scope and small sample size restricted its generalizability. This highlights the need for more comprehensive, context-specific research to understand how LAI-ART could be scaled up effectively in diverse settings across the country.

This study aims to evaluate the acceptability of LAI-ART among PLHIV in Kenya's urban settings, combining quantitative surveys and qualitative interviews to explore patient experiences and preferences. The findings will provide insights into the factors influencing LAI-ART uptake and inform policies and interventions to enhance its accessibility and effectiveness. By addressing both the benefits and challenges of LAI-ART, this research seeks to contribute to the evolving landscape of HIV care and improve health outcomes for PLHIV in Kenya and beyond.

# Materials and methods

### Study Design

This was an exploratory mixed-methods study, conducted between 8th December 2023 and 9th July 2024, that investigated the perspectives of people living with HIV regarding long-acting injectable antiretroviral therapy at two tertiary hospitals in Nairobi. Quantitative data was gathered through a survey questionnaire administered to the patients while qualitative data was obtained through three focus group discussions. The Consolidated Framework for Implementation Research (CFIR) was used to develop the conceptual framework for investigating the acceptability of long-acting injectable ART (10).

**Study Site and Participants**

The study was conducted at two major tertiary hospitals in Nairobi, Kenya: Aga Khan University Hospital (AKUH) and Kenyatta National Hospital (KNH). Aga Khan University Hospital, a private, non-profit institution, is known for its comprehensive medical services, commitment to education, and advanced research in East Africa. It serves as a leading center for managing chronic diseases, including HIV. Kenyatta National Hospital, the largest referral hospital in Kenya, offers a wide range of healthcare services and serves as a teaching hospital for medical students from the University of Nairobi. KNH also plays a critical role in providing comprehensive HIV care, supporting over 8,000 adult patients living with HIV.

Eligible participants were adults aged 18 years or older, enrolled in HIV care programs at either AKUH or KNH, and receiving antiretroviral therapy (ART) for any duration. All participants were required to provide written informed consent to take part in the study. Individuals were excluded if they were unable to provide informed consent due to cognitive impairments or language barriers, or if they had acute illnesses or severe mental health conditions that could affect their ability to participate.

The recruitment process aimed to ensure diversity by including participants from various age groups, genders, and socio-economic backgrounds. Quantitative data collection involved

probability sampling to achieve a representative sample, while purposive sampling was used to select participants for focus group discussions.

**Data Collection Procedures**

Quantitative data was collected using a structured survey administered to participants during their routine clinic visits. The survey included questions aimed at gathering demographic information, such as age, gender, and socio-economic background, as well as assessing participants' knowledge of LAI-ART, their attitudes toward this therapy, and their willingness to transition from oral antiretroviral therapy to long-acting injectable options. Participants completed the survey either in person or via an online link to the survey tool in REDCap, allowing them to respond at their convenience. The quantitative data provided measurable insights into trends, preferences, and potential barriers among the study population.

Qualitative data were collected through three focus group discussions (FGDs), each involving a diverse group of participants selected through purposive sampling to ensure variability in characteristics. Participants were approached during routine clinic visits, and the FGDs were conducted in person at the study sites, providing a comfortable and familiar environment. Each session lasted approximately 1–2 hours and was moderated by a trained research nurse (M.A.), who was experienced in facilitating group discussions and handling sensitive topics. Participants were informed of M.A.'s role as a neutral moderator with no personal interest or influence on the study outcomes.

The FGDs explored participants' perceptions of long-acting injectable antiretroviral therapy (LAI-ART), focusing on their understanding of the therapy, perceived benefits, concerns, barriers, and facilitators to adoption. A semi-structured discussion guide ensured consistency across sessions while allowing flexibility to probe emerging themes. Discussions were audio-

recorded with participant consent for accurate transcription and analysis. However, field notes were not taken, and no non-participants were present during the FGDs.

### Data Analysis

The study utilized both descriptive and inferential statistical methods to analyze the quantitative data collected through surveys. Descriptive statistics, including means, medians, standard deviations, frequencies, and percentages, were used to summarize demographic characteristics and responses related to knowledge, attitudes, and preferences regarding long-acting injectable antiretroviral therapy (LAI-ART).

To assess the relationships between categorical variables and interest in LAI-ART, chi-square tests of independence were performed. These tests examined whether the observed differences in proportions between groups, such as age categories or adherence levels, were statistically significant. A p-value threshold of $p<0.05$ was used to determine significance. Data analysis was performed using SPSS version 25.0.

Thematic analysis was employed to analyze the qualitative data from the focus group discussions. Audio recordings were transcribed verbatim, and a coding framework was developed based on the study's objectives and emergent themes from the data. Two researchers (DN and CK) independently coded the transcripts to ensure reliability, resolving any discrepancies through discussion. Transcripts were not returned to participants for validation or feedback. Data saturation was not explicitly considered during the analysis.

### Ethical Statement

Ethical approval was obtained from the relevant institutional ethics review board before initiating the research. All participants provided written informed consent after being fully briefed about the study's purpose, procedures, potential risks, and benefits. Participation was voluntary, with assurances that withdrawal would not affect access to care. Confidentiality

was maintained through anonymized data and secure storage, while focus group discussions were held in private settings to ensure privacy. A trained moderator facilitated discussions sensitively to minimize risks like stigma or discomfort. Findings were anonymized, ensuring participants could not be identified in reports.

# Results

### Qualitative results

A total of 356 participants were surveyed across two tertiary hospitals in Nairobi, with an additional subset of 30 patients participating in three focus group discussions. The survey results, focusing on demographics **(Table 1),** medical history, and associations between various variables **(S1 Table),** are outlined below.

**Table 1: Demographic characteristics**

| Variable | Frequency (%) |
|---|---|
| **Age in years** | |
| 20-29 | 31 (8.7) |
| 30-39 | 93 (26.1) |
| 40-49 | 115 (32.3) |
| 50-59 | 96 (27.0) |
| 60-69 | 20 (5.6) |
| 70-79 | 1 (0.3) |
| **Gender** | |
| Male | 146 (41.0) |
| Female | 215 (59.0) |
| **Nationality** | |

| | |
|---|---|
| Kenya | 355 (99.7) |
| Burundi | 1 (0.3) |
| **Marital status** | |
| Single | 87 (24.4) |
| Married | 218 (61.2) |
| Divorced | 7 (2.0) |
| Separated | 20 (5.6) |
| Widow(er) | 23 (6.5) |
| I prefer not to say | 1 (0.3) |
| **Do you live?** | |
| Alone | 87 (24.4) |
| As a couple | 25 (7.0) |
| With family | 244 (68.5) |
| **Type of accommodation** | |
| Lease | 218 (61.2) |
| Owner | 109 (30.6) |
| Staying with family | 26 (7.3) |
| Others | 1 (0.3) |
| I prefer not to say | 2 (0.6) |
| **Has children** | |
| Yes | 291 (81.7) |
| No | 65 (18.3) |
| **Number of children** | |
| Median (IQR) | 2 (2-3) |
| Min-Max | 1-7 |

| Number of dependent children | |
|---|---|
| Median (IQR) | 2 (1-3) |
| Min-Max | 0-7 |

The participants' duration of HIV infection ranged widely, with 35.4% living with HIV for more than 10 years, 22.2% for 5–10 years, 26.4% for 1–5 years, and 7.6% for less than 1 year (**S2 Table**). Similarly, ART treatment durations mirrored these patterns. Most participants were on a once-daily ART regimen (95.5%), and 91.6% perceived their current treatment as simple to manage. ART adherence was high, with 47.9% reporting occasional missed doses and 48.6% never missing doses. ART-related adverse events were uncommon, with 56.2% of participants reporting no adverse effects and 86.0% finding their ART regimens tolerable. Disclosure of HIV status varied, with 60.4% of participants sharing their status with their partner, 46.3% disclosing to family members, and only 12.4% and 6.5% revealing it to friends and colleagues, respectively.

### Knowledge and Awareness of LAI-ART

As shown in **Table 2**, 65.2% of participants reported being aware of long-acting injectable ART**.** Healthcare providers were the most common source of information (57.3%), followed by online resources (55.2%) and support groups (30.2%)**.** Knowledge of LAI-ART was not significantly associated with demographic or HIV-related characteristics **(S3 Table)**

**Table 2: Knowledge on injectable ART**

| Variable | Frequency (%) |
|---|---|
| **Know about LAI-ART for HIV treatment** | |
| Yes | 232 (65.2) |

| | |
|---|---|
| No | 124 (34.8) |
| **Source of information about LAI-ART (n=232)** | |
| Healthcare provider | 133 (57.3) |
| Support group | 70 (30.2) |
| Online resources | 128 (55.2) |
| Other | 3 (1.3) |
| **Ever received or considered receiving LAI-ART** | |
| Yes | 252 (70.8) |
| No | 104 (29.2) |

### Interest in LAI-ART

Overall, 72.2% of participants expressed willingness to switch to LAI-ART if offered as shown in **Table 3**. Prior knowledge of LAI-ART was strongly associated with interest, with 93.9% of participants who were aware of LAI-ART expressing interest, compared to only 80.2% of those without prior knowledge ($p < 0.001$) **(S4 Table).** Women were significantly more likely to accept LAI-ART compared to men (93.5% vs. 83.9%, $p = 0.009$). Additionally, employed participants were 2.3 times more likely to accept LAI-ART compared to their unemployed counterparts; however, this association was not statistically significant. (1.0-5.4, p=0.057). Among those willing to take LAI-ART, 25.3% agreed to receive injections every month, while 31.1% preferred every two months. A significant proportion (68.9%) expressed willingness to extend the interval beyond two months. The median preferred interval between injections was six months (IQR: 3-6 months)**.**

**Table 3: Acceptability of LAI-ART**

| Variable | Frequency (%) |
|---|---|
| **Accepts to take LAI-ART if offered** | |
| Yes | 257 (72.2) |
| No | 30 (8.4) |
| I don't have enough information | 62 (17.4) |
| I am not sure | 7 (2.0) |
| **Would agree to come every month for ART (n=257)** | |
| Yes | 65 (25.3) |
| No | 122 (47.5) |
| I don't have enough information | 50 19.5) |
| I am not sure | 6 (2.3) |
| Missing | 14 (5.4) |
| **Would agree to come every 2 months for ART (n=257)** | |
| Yes | 80 (31.1) |
| No | 103 (40.1) |
| I don't have enough information | 54 (21.0) |
| I am not sure | 4 (1.6) |
| Missing | 16 (6.2) |
| **Would agree to come if longer than 2 months for ART (n=257)** | |
| Yes | 177 (68.9) |
| No | 31 (12.1) |
| I don't have enough information | 36 (14.0) |
| I am not sure | 4 (1.6) |

| | |
|---|---|
| Missing | 9 (3.5) |
| **Shortest months between ART treatments**<br><br>Median (IQR)<br><br>Min-Max | <br><br>6 (3-6)<br><br>2-12 |

**Facilitators and Barriers to LAI-ART Adoption**

The most cited advantage was the opportunity to stop taking daily treatments, mentioned by 71.3% of participants **(S5 Table).** Half (50.3%) of participants felt that LAI-ART would help them avoid forgetting medications, underscoring its potential to enhance adherence. Additionally, 44.7% of participants appreciated the idea of not thinking about their condition daily. Privacy was another significant facilitator, with 40.7% of participants valuing the ability to hide their treatment from colleagues or surroundings. Other facilitators included the ability to forget the disease (32.6%) and maintain confidence in the effectiveness of treatment for a given period (15.1%). 76.4% of participants saw the requirement for regular injections as beneficial due to perceived increased healthcare monitoring.

Several barriers to adopting LAI-ART were identified, with the most prominent being fear of side effects, reported by 69.7% of participants. The fear of injections was another notable barrier, cited by 32.3% of participants. Additionally, 20.2% of participants were concerned about being perceived as "guinea pigs," reflecting distrust in new medical treatments and fear of being part of experimental initiatives. Other barriers, such as the belief that LAI-ART would not change their illness (7.3%) or concerns about losing the freedom to stop treatment (1.1%), were less frequently mentioned. (***Supplementary table 5)***

**Quantitative Results**

The findings are reported as themes and subthemes that emerged within the consolidated framework

### Individual Characteristics

**Knowledge and Beliefs**: Participants' knowledge and beliefs about LAI-ART varied widely. Many had learned about injectable ARVs from healthcare facilities or social media but lacked detailed information on their implementation, effectiveness, and potential side effects. One participant inquired, *"I wanted to ask. Maybe you can tell us if they have any side effects so that we get to know what to expect"* **(FGD3 R1).** Despite these concerns, most participants viewed injectable ARVs positively, particularly in addressing stigma, pill burden, and adherence challenges. A participant noted, *"I heard they are coming to Kenya, and I prefer the injectable over oral because oral can be inconvenient in case you have visitors and you fear taking the tablet.* ***The injection gives freedom"*** **(FGD1 R2).**

However, concerns about potential medical complications and fertility concerns persisted. A participant worried about adverse reactions: *"Another challenge is if it has already been injected into the body and it has to stay for 3 months but you are very reactive, it will be difficult to stop—for example, allergies"* **(FGD2 R1).** Similarly, another participant expressed concern about fertility: "*What if they inject, and at the end of the day, I won't be able to be productive?"* **(FGD2 R9).**

**Individual Stage of Change:** Participants' readiness to adopt LAI-ART varied. Some were eager to transition immediately, stating, *"I will agree to be given injection, it would have reduced the burden of taking tablets every day, and the body will get used to side effects"* **(FGD1 R9).** Others affirmed their preference for injections over tablets, with one participant noting, *"Yes. It'll be better to get injection, yes, than the tabs"* **(FGD1 R6).**

Others were more cautious, preferring to wait until the injectables had been tested further: *"If I'm honest, I won't take injectable. I will take the tablets until it has been tested on others"* **(FGD3 R7).**

**Personal Motivation:** The challenges participants faced with oral ARVs, including stigma, adherence, pill burden, and the frequency of administration, motivated their preference for injectables. One participant emphasized the benefit of improved adherence, saying*, "And me too, I prefer injection because I won't forget, and it will help me keep time*" **(FGD3 R7).**

Another participant highlighted the injectables' potential to maintain privacy for students, sharing, *"I'm saying even that injection, if it works well, it will be an advantage to the students, those who are in the schools. It will keep that secret; there won't be any trauma then"* **(FGD2 R7).**

**Inner Setting**

**Healthcare Delivery System Support:** While participants welcomed the idea of injectable ARVs, they expressed concerns about how this transition might impact the support they currently receive from healthcare providers. They requested continued health education, visit reminders, and follow-ups via home visits or phone calls to address issues such as side effects and adjustment to the new treatment. One participant explained, "*You know, when you're at this point when you're doing transitioning, a lot happens. There are so many things like the side effects and other things. So we need to have, uh, follow-up. Phones and follow-up"* **(FGD2).** Another participant suggested reintroducing existing reminder systems, saying, *"There was a reminder—they should use it again during injectables to help me to know dates and time. That would be the biggest support"* **(FGD3 R5).** Additionally, participants expressed interest in leveraging technology for support, with one suggesting, "*The apps like*

*the one we used to have that give information like weight, BMI, remind of dates, and also as we start you give us more clinics for feedback and more information"* **(FGD3 R8).**

**Availability of Resources:** Participants were concerned about the availability of injectable ARVs across all healthcare facilities and at all times. One participant asked, *"Will it be available all the time and continuous?"* **(FGD3 R5).** Another raised concerns about equitable access across the country, stating, *"Also this one, when it comes and let's say it's been accepted, it doesn't have any side effects, does it mean every county we will be going? Just like how we get our ARVs even at the county levels"* **(FGD2 R5).**

**Outer Setting**

**Stigma and Privacy Concerns:** Participants expressed significant anxiety about the stigma associated with taking antiretroviral therapy pills in public. Injectable ART was seen as a more private option, reducing the risk of being identified as living with HIV. *"For me injectable is okay, I am a housekeeper, I stay with my employer and our employers they don't like people living with HIV, they think you might affect their children. When they realize you have the tablets, they will just throw you out and add more stigma, but for injectables I will be comfortable and it will help reduce stigmatization."* **(FGD 3 R1)**

This fear was particularly pronounced among younger people, such as students, who faced the risk of being exposed at school. *"These young ones, they feel shy walking with the drugs and they fear using them in front of people… we would prefer the injectable ones that one won't feel shy anymore and you can go anywhere with it.,."* **(FGD 2 R3)**

**Social and Family Reactions:** Family judgment was another concern. Participants shared painful experiences of accidental disclosure through the visibility of pills. *"One time when my brother left and collected my belonging in my house and found my medicine, he left, took*

*alcohol and came back. I felt like killing myself... Remember he is a brother and right now he has told everyone whom they are drinking alcohol with. Let me tell you, there is nothing as painful as that."* **(FGD 2 R4)**

The emotional pain extended beyond family members, as the visibility of their current medication made participants vulnerable to gossip and judgment from outsiders. *"It's been an embarrassment I've gotten from taking the tablets. I've gotten the greatest shock. In as much as it has helped me, outside there when you get sick a little bit, people know."* **(FGD 2 R4)**

**Cultural and Societal Pressures:** Cultural norms also shaped participants' feelings about treatment. Taking pills in public was seen as deviating from social expectations, leading to feelings of shame. Injectables were seen as a way to avoid unwanted attention. *"Sometimes you hide yourself when taking pills because people start asking 'Why is she taking the pills?' With injections, nobody will know why I am going for injection."* **(FGD3 R5)**

**Interventional Characteristics**

**Side Effects:** While injectables were appreciated for their benefits, participants were cautious about potential side effects. *"Will the injection affect my sleep or cause insomnia?"* **(FGD 3 R4).** *"You know we must know the side effects."* **(FGD 2 R1)**

Another worry was the difficulty of reversing side effects, given the long-acting nature of injectables. *"Suppose you get the side effects, is it reversible or will it continue that way? Is there any other back up? What can one do to remove the medicine which is in your body already?"* **(FGD1 R7)**

**Convenience and Adherence:** Participants appreciated the potential of injectables to reduce the daily pill burden. *"I prefer injections because swallowing tablets has always been a problem for me. If I had something like an injection, I will go for that than a tablet."* **(FGD 1 R5.)**

The convenience of receiving injections every few months instead of daily doses was particularly appealing. *"The injectables are good because you don't have to worry until your next appointment."* **(FGD 3 R1).** Participants with busy lives found this particularly beneficial, as it simplified their treatment routine. *"I prefer injections because I won't forget, and it will help me keep time."* **(FGD 1 R7)**

**Flexibility and Access:** However, some participants worried about the inflexibility of injection schedules. Tablets offered portability, allowing treatment to continue while traveling, but injections required visits to healthcare facilities. *"If I am injected in Kenyatta and I travel to Western Kenya, what will I do if I can't come back for my next injection?"* **(FGD 2 R8).** "*The disadvantage of injections is that with tablets you can carry extras and reschedule if you miss."* **(FGD 3 R4).**

Participants were also concerned about the effects of missing an injection. *"What I would like to know is if I skip the dates for my injection and I come two days later what will happen?"* **(FGD1 R1)**

**Safety and Monitoring:** Participants also emphasized the need for pre-injection testing, particularly for individuals with underlying health conditions. "*Before they inject, do they test your blood??"* **(FGD 1 R5).** They also raised concerns about the suitability of the injectable ART among different demographics and in patients with underlying illnesses. "*Is it for*

*everyone like, children, adults, those who have other conditions like pressure, diabetes?" (FGD3 R8)*

Trust in the manufacturer was also important for participants. *"We need to know the manufacturer."* **(FGD3 R3).** This trust was tied to overall confidence in the safety and efficacy of the injectables.

**Long-term Commitment and Adaptation:** While participants were open to trying long-acting injectables, they expressed a preference for a trial period before committing to long-term use. *"I will take the injection for three months to weigh the side effects, then commit for a year if it reacts positively."* **(FGD 3 R1).** Others were optimistic that side effects would become manageable over time*: "The body will get used to the side effects."* **(FGD 3 R9).**

# Discussion

The findings from this study provide important insights into the acceptability of long-acting injectable antiretroviral therapy (LAI-ART) among people living with HIV (PLHIV) in Nairobi, Kenya. Overall, a majority of participants expressed interest in transitioning to LAI-ART, citing benefits such as reduced stigma, improved adherence, and convenience. However, concerns regarding potential side effects, injection-related discomfort, and accessibility were also highlighted.

**Knowledge of LAI-ART**

Our study found that approximately 65% of participants were aware of LAI-ART. While this indicates a reasonable level of awareness, it also highlights the need for broader dissemination of information about this new treatment option. Despite this level of

awareness, FGDs highlighted significant knowledge gaps regarding LAI-ART's side effects, efficacy, and availability, which contributed to hesitancy among some participant.

Interestingly, knowledge of LAI-ART was not significantly associated with demographic or HIV-related characteristics in our study. This contrasts with the broader literature on HIV knowledge and treatment, which has frequently demonstrated associations between factors such as age, education, and socioeconomic status, and various aspects of HIV-related knowledge and treatment outcomes(11–13). The lack of a significant association in our study between LAI-ART knowledge and these factors suggests that information about LAI-ART may be reaching diverse segments of the PLHIV population.

The most common sources of information about LAI-ART reported by our participants were healthcare providers, online resources, and support groups. This highlights the importance of engaging these channels in future educational campaigns. Healthcare providers, in particular, play a crucial role in providing accurate and personalized information about LAI-ART to their patients. Training healthcare providers on LAI-ART and equipping them with the necessary resources to address patient questions and concerns will be essential for successful implementation. Online resources and support groups can also serve as valuable platforms for disseminating information and fostering peer support among individuals considering LAI-ART.

**Acceptability and Willingness to Transition**

The high level of willingness (72.2%) to transition to LAI-ART observed in our study is consistent with findings from similar studies conducted in diverse global settings. For instance, in a study conducted among female sex workers living with HIV from the Dominican Republic and Tanzania, 85% of FSW in the Dominican Republic (DR) and 92%

in Tanzania indicated they were likely or very likely to use LA ART if available(8). Our findings also align with previous qualitative research in Kenya, where participants expressed strong interest in LAI-ART particularly as a solution to challenges with daily ART(9). These consistent findings across different contexts suggest that the desire for less frequent and less stigmatizing treatment options is a strong motivator for PLHIV globally.

Prior awareness of LAI-ART was a significant predictor of interest. Participants who had prior knowledge of the therapy were considerably more likely to express willingness to transition, reinforcing the importance of targeted educational campaigns to increase uptake. This finding is consistent with the broader literature on health behavior change, which emphasizes the role of knowledge and awareness in influencing adoption of new interventions(14–16).

Notably, women in our study showed greater enthusiasm for LAI-ART compared to men. Our finding contrasts with a recent study conducted in Spain(17), which reported greater interest among men. This discrepancy highlights the importance of considering contextual factors, such as cultural norms, healthcare access, and gender roles, when interpreting gender-related preferences for LAI-ART. It is possible that varying levels of comfort with injections, differing perceptions of risk and benefit, or culturally specific experiences of stigma may contribute to these observed differences. Further research is needed to explore the specific factors driving these gender differences in LAI-ART preference across diverse settings. Understanding these differences is crucial for tailoring LAI-ART implementation strategies to the specific needs and preferences of both men and women.

One of the primary drivers of LAI-ART acceptability in our study was the desire to eliminate the burden of daily oral ART. Participants expressed a strong preference for a treatment modality that would free them from the daily routine of taking pills. These observations are

consistent with findings by Simoni et al. (2021)(9), which demonstrated that simplified regimens enhance patient satisfaction and engagement in care.

Increased privacy was another important facilitator of LAI-ART acceptability. Many participants valued the ability to manage their HIV treatment more discreetly, reducing the risk of unintentional disclosure and the associated stigma. This finding highlights the ongoing challenges related to stigma and discrimination faced by PLHIV. Studies have consistently shown that stigma remains a significant barrier to HIV care and treatment(18–21). LAI-ART offers a potential way to mitigate these challenges by allowing individuals to maintain greater privacy regarding their treatment.

**Barriers to Adoption**

Despite the overall enthusiasm, concerns about side effects emerged as the most significant barrier, with nearly 70% of participants citing apprehensions regarding potential adverse reactions. Participants in our study expressed fear of unknown side effects, the difficulty of reversing adverse reactions given the long-acting nature of the drug, and concerns about the impact on fertility. This finding aligns with the study by Simoni et al. (2019)(7), where fears of irreversible or prolonged side effects deterred patients from transitioning to injectable ART. However, clinical trials, including the pivotal study by Swindells et al. (2020)(4), have demonstrated that LAI-ART is both safe and effective, with a side effect profile comparable to that of oral ART. These concerns highlight the necessity for comprehensive patient education and post-injection follow-up support to address safety concerns and build trust in LAI-ART.

Another notable barrier was fear of injections, reported by 32.3% of participants. While needle phobia was not a universal issue, it presents a challenge that should be factored into

the implementation strategy.  Strategies such as patient counseling, the use of smaller-gauge needles to minimize discomfort, and potentially even offering alternative administration techniques (if available in the future) could be explored to alleviate this concern.

Distrust in medical innovation was another significant barrier, with 19.6% of survey participants expressing concerns about being perceived as "guinea pigs" for new therapies. This sentiment was amplified in the FGDs, where participants questioned the long-term safety and reliability of LAI-ART. This skepticism aligns with findings from studies in Tanzania and the Dominican Republic, where similar doubts about new HIV treatments were documented(8). Such distrust often stems from a lack of accessible, transparent information about the development and approval processes for new therapies.

Logistical challenges, particularly the need for regular clinic visits for injections, were also seen as a limitation. Similar findings from Mantsios et al. (2021)(6) emphasized the logistical burden of clinic-based administration, particularly in low-resource settings. FGDs further highlighted participants viewed the portability of oral ART as a distinct advantage over injectables. Expanding delivery options, such as home-based or pharmacy-based administration, could mitigate logistical challenges and improve accessibility

Participants emphasized the need for robust healthcare support to ensure a smooth transition to LAI-ART. FGDs revealed that pre-injection health checks, regular follow-ups, and reminders were seen as essential for maintaining adherence. Digital tools, such as SMS reminders, were particularly appealing, aligning with findings from Mantsios et al. (2021)(6), which highlighted the importance of patient-centered approaches in enhancing the success of LAI-ART. Furthermore, participants expressed a desire for detailed counseling sessions to address potential side effects and ensure informed decision-making.

Concerns about the equitable availability of LAI-ART across urban and rural settings were a recurring theme. Participants questioned whether decentralized healthcare facilities, particularly in rural areas, would have the infrastructure to support LAI-ART delivery. These concerns are consistent with key informant views in Kilifi, Kenya(9), where logistical issues, including access to clinics and potential need for refrigeration, were identified as challenges for successful implementation.

# Conclusion

This study highlights strong interest in long-acting injectable antiretroviral therapy (LAI-ART) among people living with HIV in Nairobi, driven by its potential to improve adherence and reduce stigma. However, concerns about side effects, needle phobia, and logistical challenges must be addressed. To achieve successful implementation, it is essential to provide targeted education, train healthcare providers, and establish strong support structures.

# Acknowledgments

We sincerely appreciate the study participants and research teams from Kenyatta National Hospital and Aga Khan University Hospital for their time, dedication, and commitment to this work

# Reference

1. UNAIDS/WHO. Global HIV Programme. World Health Organisation. 2023;1–4.
2. Kenya | UNAIDS [Internet]. [cited 2023 Jan 28]. Available from: https://www.unaids.org/en/regionscountries/countries/kenya
3. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection | FDA [Internet]. [cited 2023 Jan 30]. Available from: https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection

4. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. New England Journal of Medicine. 2020;382(12):1112–23.

5. Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021 Nov 1;8(11):e668–78.

6. Mantsios A, Murray M, Karver TS, Davis W, Galai N, Kumar P, et al. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. BMC Health Serv Res [Internet]. 2021 Dec 1 [cited 2024 Jan 7];21(1):1–14. Available from: https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-021-06214-9

7. Simoni JM, Beima-Sofie K, Mohamed ZH, Christodoulou J, Tapia K, Graham SM, et al. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV. AIDS Patient Care STDS [Internet]. 2019 Mar 3 [cited 2023 Jan 29];33(3):104. Available from: /pmc/articles/PMC6442271/

8. Kerrigan D, Sanchez Karver T, Muraleetharan O, Savage V, Mbwambo J, Donastorg Y, et al. “A dream come true”: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS One [Internet]. 2020 Jun 12;15(6):e0234666. Available from: https://doi.org/10.1371/journal.pone.0234666

9. Simoni JM, Beima-Sofie K, Wanje G, Mohamed ZH, Tapia K, McClelland RS, et al. “Lighten This Burden of Ours”: Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya. Journal of the International Association of Providers of AIDS Care (JIAPAC) [Internet]. 2021;20:23259582211000516. Available from: https://doi.org/10.1177/23259582211000517

10. Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implementation Science [Internet]. 2022;17(1):75. Available from: https://doi.org/10.1186/s13012-022-01245-0

11. Teshale AB, Yeshaw Y, Alem AZ, Ayalew HG, Liyew AM, Tessema ZT, et al. Comprehensive knowledge about HIV/AIDS and associated factors among women of reproductive age in sub-Saharan Africa: a multilevel analysis using the most recent demographic and health survey of each country. BMC Infect Dis [Internet]. 2022;22(1):130. Available from: https://doi.org/10.1186/s12879-022-07124-9

12. Nutakor JA, Zhou L, Larnyo E, Addai-Dansoh S, Cui Y, Kissi J, et al. A multiplicative effect of Education and Wealth associated with HIV-related knowledge and attitudes among Ghanaian women. BMC Public Health [Internet]. 2023;23(1):1397. Available from: https://doi.org/10.1186/s12889-023-16311-5

13. Dinçer M, Köse N, Ünal E. The role of socioeconomic and behavioral factors in HIV-related deaths. Humanit Soc Sci Commun [Internet]. 2024;11(1):1588. Available from: https://doi.org/10.1057/s41599-024-04121-y

14. Mahalakshmi S, Suresh S. Barriers to Cancer Screening Uptake in Women: A Qualitative Study from Tamil Nadu, India. Asian Pac J Cancer Prev [Internet]. 2020 Apr 1 [cited 2025 Feb 11];21(4):1081. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7445965/

15. Den Braver NR, Bengoechea EG, Messing S, Kelly L, Schoonmade LJ, Volf K, et al. The impact of mass-media campaigns on physical activity: a review of reviews through a policy lens. The European Journal of Public Health [Internet]. 2022 Dec 1 [cited 2025 Feb 11];32(Suppl 4):iv71. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9706123/

16. Pristianty L, Hingis ES, Priyandani Y, Rahem A. Relationship between knowledge and adherence to hypertension treatment. J Public Health Afr [Internet]. 2023 [cited 2025 Feb 11];14(Suppl 1):2502. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10365644/

17. Moreno C, Izquierdo R, Alejos B, Hernando V, de la Cámara SP, Peraire J, et al. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain. AIDS Patient Care STDS [Internet]. 2024 Jul 1 [cited 2025 Feb 11];38(7):305–14. Available from: https://pubmed.ncbi.nlm.nih.gov/38916077/

18. Rueda S, Mitra S, Chen S, Gogolishvili D, Globerman J, Chambers L, et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. BMJ Open [Internet]. 2016 Jul 1 [cited 2025 Feb 11];6(7):e011453. Available from: https://bmjopen.bmj.com/content/6/7/e011453

19. Turan B, Budhwani H, Fazeli PL, Browning WR, Raper JL, Mugavero MJ, et al. How Does Stigma Affect People Living with HIV? The Mediating Roles of Internalized and Anticipated HIV Stigma in the Effects of Perceived Community Stigma on Health and Psychosocial Outcomes. AIDS Behav [Internet]. 2017 Jan 1 [cited 2025 Feb 11];21(1):283. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5143223/

20. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc [Internet]. 2013 Nov 1;16(3S2):18640. Available from: https://doi.org/10.7448/IAS.16.3.18640

21. Treves-Kagan S, Steward WT, Ntswane L, Haller R, Gilvydis JM, Gulati H, et al. Why increasing availability of ART is not enough: a rapid, community-based study on how HIV-related stigma impacts engagement to care in rural South Africa. BMC Public Health [Internet]. 2016;16(1):87. Available from: https://doi.org/10.1186/s12889-016-2753-2

# Supporting Information

**S1 Table: Lifestyle and habits**

**S2 Table: HIV infection history**

**S3 Table: Demographic characteristics associated with knowledge about LAI-ART**

**S4 Table: Demographic characteristics, lifestyle factors and medical history associated with acceptability of LAI-ART**

**S5 Table: Attitudes and perceptions towards LAI-ART**